DEC 15 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Joachim MIERAU

Serial No.: 10/801,286

Group Art Unit: 1614

Filed: March 16, 2004

Examiner: Phyllis G. Spivak

For: PRAMIPEXOLE FOR THE REDUCTION OF EXCESSIVE FOOD INTAKE FOR

CHILDREN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);				
		within three months of the actual filing date of the national phase of a PCT application; OR				
		before the mailing of a first substantive office action (including after filing of an RCE).				
\boxtimes	Unde	r 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods				

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

12/18/2006 HMARZII 00000037 10801286

02 FC:1806

180.00 OP

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
		\boxtimes	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		-	s of materials listed but not attached were cited in an international search dated
		Not re	quired by 37 CFR § 1.98.
	\boxtimes	Copies	s of the materials listed are attached (except for the foregoing).

Non-E	English	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art
		O = non-written disclosure
		P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
•		Translation of other relevant information on foreign search report
		[insert necessary translation here]
Other	Informa	ation_
Pavme	ent of Fe	ees Due (If Any):
\boxtimes		ck for \$180.00 covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

John A. Sopp, Reg. No. 33,103

Apparent Authority


MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BIC-1472

Date: December 15, 2006

JAS:blb

K:\BIC\1472\Information Disclosure Statement 12-14-06.d∞



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or form 1449A/PT	0			Complete if Known
		DIO 0	001105	Application Number	10/801,286
	RMATION			Filing Date	March 16, 2004
STATI	EMENT B	SY APP	LICANT	First Named Inventor	Joachim MIERAU
				Group Art Unit	1614
(u	use as many sh	eets as ne	cessary)	Examiner Name	Phyllis G. Spivak
Sheet	1	of	1	Attorney Docket Number	BIC-1472

		大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大大		
	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	1	Brain Res. 2001 Jun 29; 905 (1-2): 44-53. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Anderson DW, Neavin T, Smith JA, Schneider JS.		
	2	Jpn L Pharmacol. 1997 May; 74 (1): 51-7. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y.		
	3	Neurology. 2002 Feb 26; 58 (4 Supp 1): S33-41. The role of dopamine agonists in the treatment of early Parkinson's disease. Olanow CW.		
-	4	Neurology. 2002 Feb 26; 58 (4 Suppl 1): S9-18. Neuroprotection and dopamine agonists. Schapira AH.		
	5	Neurosci Lett. 2000 Mar 10; 281(2-3): 167-70. Pramipexole inhibits lipid peroxidation and reduces injury in the substania nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W.		
Examine Signatur		Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.